Episode

Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Podcast: Decera Clinical Education Oncology Podcast
Published: Jun 30, 2026
Duration seconds: 1444
Processing state: not_requested
Canonical source: https://oncologypodcast.simplecast.com/episodes/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer-9JQWI05_
Audio: https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/fe7f0e31-5428-45e0-be14-2351bccbcc23/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=fe7f0e31-5428-45e0-be14-2351bccbcc23&feed=GlfUTtJq
JSON: /v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer
Markdown: /podcast/decera-clinical-education-oncology-podcast-1302999/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer.md

Actions

POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Listen to this conversation between Cristina Saura Manich, MD, PhD, and Giampaolo Bianchini, MD, as they discuss practical approaches to PI3K pathway testing, emerging PI3K and AKT-targeted treatment options, and sequencing therapy for patients with metastatic breast cancer following development of endocrine therapy resistance.